Novel pneumococcal vaccine formulations

Abstract

Immunogenic composition are provided comprising PnCo and/or GlpO polypeptides identified as being preferentially expressed during the virulent phase of an infection related to streptococcal bacteria. The compositions can be used for eliciting immune response against streptococcal infections, such as against infections caused by S. pneumoniae.

1 . A composition comprising an immunologically effective amount of an isolated PncO polypeptide having a sequence of SEQ ID NO:1, or having at least 90% homology to SEQ ID NO:1, in a pharmaceutical carrier. 
     
     
         2 . The composition of  claim 1 , where the only immunological component is PncO. 
     
     
         3 . The composition of  claim 1 , further comprising isolated GlpO having a sequence of SEQ ID NO:2, or having at least 90% homology to SEQ ID NO:2. 
     
     
         4 . The composition of  claim 1 , further comprising an adjuvant. 
     
     
         5 . The composition of  claim 1 , wherein the polypeptide is incorporated in a delivery vehicle. 
     
     
         6 . The composition of  claim 5 , wherein the delivery vehicle is a nanovesicle, nanoparticle, microvesicle, or hybrid delivery vehicle. 
     
     
         7 . A nanovesicle having incorporated therein a PncO polypeptide having a sequence of SEQ ID NO:1 or having at least 90% homology to SEQ ID NO:1, and/or a GlpO polypeptide having a sequence of SEQ ID NO:2 or having at least 90% homology to SEQ ID NO:2. 
     
     
         8 . The nanovesicles of  claim 7 , wherein the nanovesicle comprises porphyrin phospholipid conjugates having cobalt chelated thereto. 
     
     
         9 . A method of eliciting an immune response in an individual against streptococcal infection comprising administering to the individual an effective amount of a composition of  claim 1 . 
     
     
         10 . The method of  claim 9 , wherein the elicited immune response is protective against an infection caused by  S. pneumoniae.    
     
     
         11 . The method of  claim 10 , wherein the infection caused by  S. pneumoniae  is pneumonia. 
     
     
         12 . The method of  claim 9 , wherein the polypeptide in the composition is incorporated into a nanovesicle, wherein the nanovesicle comprises porphyrin phospholipid conjugates having cobalt chelated thereto. 
     
     
         13 . The method of  claim 9 , wherein the polypeptide in the composition is incorporated into a hybrid biological delivery vehicle. 
     
     
         14 . The method of  claim 9 , wherein the composition comprises an adjuvant. 
     
     
         15 . The method of  claim 12 , wherein the nanovesicle has an adjuvant incorporated therein. 
     
     
         16 . The method of  claim 13 , wherein the hybrid delivery vehicle has an adjuvant incorporated therein.